Cipla receives final approval for the generic version of Somatuline® Depot (Lanreotide) Injection 120 mg/ 0.5 mL, 90 mg/0.3 mL, 60 mg/0.2 mL

MUMBAI, India and WARREN, N.J., May 22, 2024 /PRNewswire/ — Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) and its wholly owned subsidiary Cipla USA Inc., (hereafter referred to as “Cipla”), today announced that it has received the final approval for its…